Boston Scientific (BSX) Issues FY 2019 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its FY 2019 earnings guidance on Wednesday morning. The company provided EPS guidance of $1.53-1.58 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.58. The company issued revenue guidance of $10.511-10.707 billion, compared to the consensus revenue estimate of $10.66 billion.Boston Scientific also updated its Q1 2019 guidance to $0.35-0.36 EPS.

A number of equities analysts have commented on the stock. Oppenheimer set a $38.00 target price on shares of Boston Scientific and gave the stock a hold rating in a research note on Wednesday, October 24th. Zacks Investment Research downgraded shares of Boston Scientific from a hold rating to a sell rating in a research note on Monday, December 31st. BTIG Research restated a buy rating and issued a $45.00 target price on shares of Boston Scientific in a research note on Thursday, October 25th. Stephens restated a market perform rating and issued a $40.00 target price on shares of Boston Scientific in a research note on Monday, November 19th. Finally, Needham & Company LLC restated a buy rating and issued a $43.00 target price on shares of Boston Scientific in a research note on Tuesday, January 8th. Three research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $40.12.

Shares of BSX opened at $37.75 on Wednesday. Boston Scientific has a fifty-two week low of $25.04 and a fifty-two week high of $39.44. The company has a market capitalization of $52.24 billion, a PE ratio of 29.96, a price-to-earnings-growth ratio of 2.20 and a beta of 0.83. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.78 and a quick ratio of 0.56.

In other news, SVP Arthur C. Butcher sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $38.50, for a total value of $154,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Maulik Nanavaty sold 3,038 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $35.46, for a total transaction of $107,727.48. The disclosure for this sale can be found here. Insiders sold a total of 95,724 shares of company stock valued at $3,504,373 in the last ninety days. Corporate insiders own 0.73% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://theenterpriseleader.com/2019/02/06/boston-scientific-bsx-issues-fy-2019-earnings-guidance.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: Coverage Ratio

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply